PTC Therapeutics (NASDAQ:PTCT) Given New $95.00 Price Target at TD Cowen

Posted by Brian Himes on Oct 31st, 2026

PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target boosted by TD Cowen from $90.00 to $95.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on PTCT. Truist Financial assumed coverage on PTC Therapeutics in a research note on Friday, October 16th. They issued a “hold” rating and a $62.00 target price on the stock. Wall Street Zen cut PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. UBS Group started coverage on PTC Therapeutics in a research report on Thursday, October 15th. They set a “buy” rating and a $90.00 price target for the company. Morgan Stanley boosted their price target on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Zacks Research lowered PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $95.64.

Read Our Latest Research Report on PTC Therapeutics

PTC Therapeutics Stock Performance

NASDAQ:PTCT opened at $59.97 on Friday. PTC Therapeutics has a one year low of $58.80 and a one year high of $90.87. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of -42.84, a PEG ratio of 1.95 and a beta of 0.49. The firm’s fifty day moving average is $65.36 and its two-hundred day moving average is $70.78.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The business had revenue of $357.81 million during the quarter, compared to analyst estimates of $306.43 million. The business’s revenue was up 69.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.20 EPS. As a group, equities research analysts predict that PTC Therapeutics will post 1.19 earnings per share for the current fiscal year.

Insider Activity

In other PTC Therapeutics news, Director Michael Schmertzler sold 12,500 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $72.94, for a total value of $911,750.00. Following the completion of the transaction, the director owned 1,349,094 shares in the company, valued at approximately $98,402,916.36. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Steele, Jr. sold 12,000 shares of the stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $65.16, for a total transaction of $781,920.00. Following the sale, the director directly owned 22,500 shares in the company, valued at approximately $1,466,100. The trade was a 34.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,370 shares of company stock worth $5,322,261 over the last three months. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in PTC Therapeutics in the third quarter valued at approximately $276,000. Profund Advisors LLC increased its position in shares of PTC Therapeutics by 56.2% in the third quarter. Profund Advisors LLC now owns 35,877 shares of the biopharmaceutical company’s stock valued at $2,324,000 after buying an additional 12,904 shares in the last quarter. Vise Technologies Inc. raised its stake in shares of PTC Therapeutics by 3.1% during the 3rd quarter. Vise Technologies Inc. now owns 8,826 shares of the biopharmaceutical company’s stock worth $572,000 after buying an additional 266 shares during the period. State of Wyoming raised its stake in shares of PTC Therapeutics by 15.3% during the 3rd quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 260 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of PTC Therapeutics by 15.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,228 shares of the biopharmaceutical company’s stock worth $989,000 after buying an additional 2,027 shares during the period.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.